The effects of intermittent administration of human parathyroid hormone (1–34) on streptozotocin-induced diabetic rats

Intermittent administration of low doses of human parathyroid hormone (h-PTH) has been reported to exhibit an anabolic effect on bone, increasing its mass. We investigated the effects of intermittent administration of h-PTH on bone changes in streptozotocin- (STZ-) induced diabetes mellitus (DM) rats by measuring bone mineral density and bone mineral contents and by bone histomorphometry. Wistar rats, 7–8 months old, were used. Osteoporosis was induced by diabetes mellitus, which was established by an intraperitoneal injection of STZ. Rats were separated into five groups: sham-injected, baseline control, vehicle-only-administered, and low-dose (6.0μg/kg) or high-dose (60.0μg/kg) h-PTH-administered groups. h-PTH or vehicle was injected subcutaneously six times a week for 4 weeks beginning 9 weeks after STZ administration. Bone mineral density and mineral contents were significantly lower in the baseline control and vehicle groups than in the control group. The PTH-administered groups showed higher values compared with both vehicle and baseline control groups. In bone histomorphometry, both bone volume and bone formation in the STZ group were markedly reduced. The h-PTH-administered rats showed increase in both bone volume and bone formation, which are related parameters, but administration of h-PTH did not alter the extent of eroded surface. Our results suggest that intermittent administration of h-PTH is effective in activating bone formation and in preventing further bone loss in osteoporosis developed by STZ-induced DM.     

国产鼻喷鲑鱼降钙素治疗骨质疏松性疼痛的疗效观察

目的观察国产鼻喷鲑鱼降钙素治疗骨质疏松性疼痛的疗效。方法采用随机分组对照设计。选择骨质疏松患者53例,随机分为两组,治疗组(30例)给予鼻喷鲑鱼降钙素,20u/次,1次/天,8周为1个疗程,停药后继续观察3周。对照组(23例)口服钙尔奇D片,1片/次,1次/天,共8周;采用国际惯用分级标准对疼痛予以评估。结果治疗组患者的疼痛明显改善,其总有效率为95%;在停药后缓解疼痛的作用仍可维持4周以上,Ⅲ度骨质疏松患者的治疗效果较Ⅰ度和Ⅱ度患者的效果差;对照组症状未见明显改善。结论用国产鼻喷鲑鱼降钙素治疗骨质疏松性骨痛,可明显缓解患者的疼痛症状。     

低剂量激素替代治疗对绝经后妇女骨代谢的影响

目的 探讨低剂量结合型雌激素（ＣＥ）和安宫黄体酮（ＭＰＡ）联合应用对骨代谢的影响，方法３４例绝经后妇女随机分为两组，试验组１７例，ＣＥ０．６２５ｍｇ与ＭＰＡ２ｍｇ隔日口服交替应用，对照组１７例，口服ＣＤ０．６２５ｍｇ／ｄ，每月连续服用２５ｄ，后１０ｄ加用ＭＰＡ４ｍｇ。两组均连续服用４周期，于用药前后分别测定血碱性磷酸酶（ＡＬＰ）及尿Ｃａ／Ｃｒ比值。结果 实验组完成治疗者１６例，对照组完成治疗者１５     

糖尿病患者第3腰椎骨密度测量的意义

糖尿病（ＤＭ）患者继发骨质疏松较多见，为探讨早期诊断，对３０例非胰岛素依赖型糖尿病（ＮＩＤＤＭ）患者和４０例正常对照者，进行血清钙（Ｃａ）、磷（Ｐ）、碱性磷酸酶（ＡＫＰ）的测定，拍照胸部、腰椎和骨盆Ｘ线片，并分别经ＣＴ进行第３腰椎骨密度（ＢＭＤ）测量。结果，ＤＭ组ＢＭＤ均值为１２７．１±２５．７７ｍｇ／ｃｍ３，对照组ＢＭＤ均值为１８９．１１±７１．６８ｍｇ／ｃｍ３，两组比较有非常显著差异（Ｐ＜０．０１），提示第３腰椎骨密度测量对ＤＭ患者骨质疏松的早期诊断有一定价值。     

基于骨免疫微环境探讨补肾活血方防治绝经后骨质疏松症的研究进展

骨质疏松症（OP）是我国人群中最常见的多发病,好发于绝经后的老年妇女,增加了患者骨折的风险。绝经后骨质疏松症（PMOP）是一种以骨量减少和骨折风险增加为特征的全身性疾病,主要是绝经后雌激素水平显著降低导致的。除了雌激素缺乏对骨骼的直接负面影响外,绝经后妇女免疫状态的改变间接导致骨骼的持续破坏,因为绝经后妇女通常表现出慢性低级别炎症表型,细胞因子表达和免疫细胞谱发生改变。PMOP已严重危害我国女性健康。补肾活血方是一种应用广泛的补肾活血中药,近年来,随着我国临床医师与患者越来越重视中医药,补肾活血方被应用于多种疾患,包括骨科的多种疾病,其对PMOP的防治效果亦明显。该文基于骨免疫微环境,以骨代谢对PMOP产生影响为基础,论述补肾活血方的作用机制。     

行气活血补肾壮骨方在双膦酸盐药物休假期患者的临床观察

摘要：目的：观察益气活血补肾壮骨方在骨质疏松症(气滞血瘀型)患者双膦酸盐药物休假期的临床疗效和不良反应等。方法：将本院2019年12月—2021年7月就诊120例气滞血瘀型骨质疏松症双膦酸盐药物休假期患者按照随机数字表均分为两组。对照组予钙片、阿法骨化醇胶囊、金天格治疗,研究组予钙片、阿法骨化醇胶囊加用益气活血补肾壮骨方治疗。治疗6个月后,比较两组患者骨代谢、细胞因子、骨密度、 健康调查简表(SF-36评分)、脆性骨折发生率、骨折风险评估、中医证候积分、疗效和不良反应等。结果：治疗前两组各项指标比较差异无统计学意义(p>0.05)。治疗后研究组骨代谢低于对照组（BGP25.69±4.07vs26.37±4.16ng/mL、PINP35.79±7.38vs37.02±8.12ng/mL、CTX0.85±0.14vs1.26±0.21mmol/L、TRACP8.93±1.26vs13.06±2.59u/L）,细胞因子(IL-1:26.36±3.07vs23.75±2.93pg/mL、IL-6:82.71±6.25vs78.62±9.08pg/mL、TNF-α5.03±1.02vs3.81±1.09ng/L)高于对照组,差异有统计学意义（p<0.05）。研究组SF-36评分(87.46±8.32vs70.62±6.59)、西医有效率(86%vs80%)、中医症候积分(23.46±5.32vs21.62±4.59)、中医疗效有效率(84%vs76%)高于对照组,左股骨颈BMD(0.68±0.05vs0.70±0.06g/cm2),脆性骨折发生率(2%vs8%)、骨折风险评估(1.49±0.32vs2.63±0.47)低于对照组,但差异无统计学意义(p>0.05)。结论：益气活血补肾壮骨方联合钙片、阿法骨化醇胶囊可改善双膦酸盐药物假期患者(气滞血瘀型)骨代谢水平,抑制骨吸收和炎性因子水平、促进骨形成、提高骨密度,降低脆性骨折发生率和骨折风险,提高中医症候积分、生活质量,从而提高疗效,疗效水平与金天格相当。     

续断对大鼠骨质疏松性骨折愈合影响的生物力学实验研究

目的:观察续断对大鼠去卵巢骨质疏松性骨折模型骨折愈合中生物力学性能的影响。材料与方法:选取30只4月龄大鼠,分为假手术骨折对照组、去卵巢骨折对照组、去卵巢骨折中药处理组。后两组去卵巢3月造成绝经后骨质疏松模型,之后三组均造成桡骨远端骨折,灌药1月后检测桡骨骨痂生物力学强度。结果:中药处理组最大剪切力17.76±1.25N,剪切应力1.12±0.13N/mm2,生物力学性能与基础骨折对照组相接近,明显优于去卵巢骨折对照组(P<0.01)。结论:续断能改善骨质疏松性骨折愈合骨痂的生物力学性能,具有一定的促进骨折愈合的作用。     

低强度脉冲电磁场对大鼠骨质疏松的影响

目的：观察低强度脉冲电磁场（pulsed electromagnetic fields，PEMFs）对去卵巢诱导骨质疏松症的大鼠生化指标和骨应力的影响。方法：雌性SD大鼠30只，随机等分为3组（n=10），分别为假手术组（Sham）、骨质疏松模型组（Model）、脉冲电磁场照射组（PEMFs）。经适应4wk后，在25mg·Kg^-1戊巴比妥钠腹腔麻醉下，Model组和PEMFs组摘除双侧卵巢．Sham组找到但不切除卵巢。各实验组均在相同环境下饲养，模型制备4wk后开始治疗，由GZY型低强度低频率脉冲电磁场发生仪产生低频脉冲磁场，根据实验要求，我们使用亥姆霍兹线圈形成均匀磁场，PEMFs组经照射刺激治疗，频率14．3Hz，场强2Gs．日照8h。Model组和Sham组正常饲养。治疗8wk后，对各组大鼠血清、尿液中ALP和Ca以及骨应力进行检测。结果：（1）ALP、Ca检测结果：与Model组相比，PEMFs组ALP值、Ca值差异均有统计学意义（P〈0．05）。其中，血清中ALP值，Model组为（275．16±228，57），PEMFs组为（179．30±87．68）；Ca值，Model组为（2，66±0，13），PEMFs组为（2．52±0．05）。（2）骨应力检测结果：Model组为（923．60±34．15Pa），PEMFs组为（1152．85±118，20Pa），组间差异有统计学意义（P〈0．05）。结论：研究发现，PEMFs对于促进骨重建、提高Ca吸收和骨应力恢复具有积极作用。     

Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis

BACKGROUND: Long-term post-menopausal hormone therapy (pHT) was often regarded as first-line therapy to prevent fractures in post-menopausal women, a recommendation under scrutiny given the benefit-risk profile of the Women's Health Initiative results of the estrogen-progestin combination. Apart from controlled clinical studies providing data with fractures as an end point, measures of lumbar and hip bone mineral density (BMD) may be used to assess bone-related effects of pHT. The objective of this study was to conduct a systematic review of 2-year trials, published between 1990 and December 2002, and assessing changes in BMD by any estrogen including ethinyl estradiol, any estrogen plus any progestin, or tibolone. METHODS: We searched MEDLINE, EMBASE and systematic reviews. Thirty-nine randomized, prospective, controlled 2-year trials were analysed in pre-specified groups according to the profile of the compounds. RESULTS: Virtually all pHT regimens at least maintain BMD at the lumbar spine and the hip compared with baseline; there is no apparent difference between the various estrogenic compounds. Tibolone, a synthetic progestin, appears to be as effective as any estrogen. Most trials were conducted in early post-menopausal women, fewer in women with hysterectomy and/or bilateral oophorectomy. CONCLUSIONS: The size of impact on BMD does not appear to differ between tibolone and any estrogen compound studied.